BSX · Investment summary · as of 12 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
Size is the strategy's, set against its own position and exposure limits.
At $51.42, BSX requires a 5% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 14%.
The market's disagreement with the business is about GROWTH DURABILITY, not margin. BSX's margin is at an eleven-year high and rising (+2.75pp TTM vs prior-TTM); what collapsed is the growth rate (organic 16% -> a guided 3-5% quarter) and with it the multiple.
The value rests on an exit multiple of 19.1x, a terminal operating margin of 20% and a 7.5% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: a multi-year growth reset in which the two franchises that produced the 2024-25 re-rating both go ex-growth simultaneously, with no offsetting franchise until 2028.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The market's disagreement with the business is about GROWTH DURABILITY, not margin. |
| What do we forecast? | Revenue growth of 14% demonstrated; a terminal operating margin of 20%; an exit multiple of 19.1x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +8.9 percentage points. |
| What is it worth? | Twelve-month target $55.00, +7% from the struck price. Scenario-weighted expected return net of costs +7.0%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 28 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
| Q3 2026 (~Oct 2026) onward | EP franchise organic growth, YoY | Global Electrophysiology organic growth is negative (at or above 0%) in any two consecutive quarters | Global Electrophysiology organic growth is negative (below 0%) in any two consecutive quarters |
| Q3 2026 onward | WATCHMAN business-unit revenue, YoY | WATCHMAN global revenue declines no more than 10% YoY in any quarter | WATCHMAN global revenue declines more than 10% YoY in any quarter |
| ~Feb 2027 | FY2027 organic revenue growth guidance | FY2027 organic revenue growth guided at or above 4% | FY2027 organic revenue growth guided below 4% |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
A multi-year growth reset in which the two franchises that produced the 2024-25 re-rating both go ex-growth simultaneously, with no offsetting franchise until 2028.
Estimated probability 35%, against the 45% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
Hard valuation trim if EV/NTM-revenue exceeds 5.0x on the forward count - that multiple was formed at a growth rate the company has retired and would represent the market re-paying for it without the growth having returned. On approach to the $55.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | A multi-year growth reset in which the two franchises that produced the 2024-25 re-rating both go ex-growth simultaneously, with no offsetting franchise until 2028. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +8.9 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: a multi-year growth reset in which the two franchises that produced the 2024-25 re-rating both go ex-growth simultaneously, with no offsetting franchise until 2028. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $45.25, which forces an immediate review.